Baseline and Early Treatment Factors Are not Clinically Useful for Predicting Individual Response to Erythropoietin in Anemic Cancer Patients

Baseline and Early Treatment Factors Are not Clinically Useful for Predicting Individual Response to Erythropoietin in Anemic Cancer Patients Timothy J. Littlewood, Martin Zagari, Christopher Pallister, Alan Perkins Oncologist 2003; 8: 99-107 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in symptom management and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Recognize that anemia is common in patients with malignant disease. Appreciate that treatment with recombinant erythropoietin can increase the hemoglobin concentration by 2g/dL or more in 70% of patients at the usual doses and frequency. Recognize that factors that predict for a hemoglobin response lack sensitivity and specificity. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Feb. 24, 2003 Most Recent Review: Feb. 24, 2003 Most Recent Update: Feb. 24, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online